Navigation Links
Greenphire's ClinCard Technology Platform selected by top 5 pharmaceutical company for long-term global clinical trial
Date:11/6/2012

KING OF PRUSSIA, Pa., Nov. 6, 2012 /PRNewswire-iReach/ -- Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced that a top 5 pharmaceutical company will use its ClinCard Technology Platform in a large, phase III clinical trial.  The trial will include over 1,000 patients across 6 countries and is expected to last over five years. 

The ClinCard system will allow the sponsor to execute quick and accurate payments to patients globally in 4 different currencies and will reduce the administrative burden on sites by replacing traditional manual processes with automated electronic payments. In previous studies, ClinCard has decreased time spent on administrative tasks related to patient payments by up to 90% and has reduced associated costs by up to 60%. In addition to reducing time and costs for clinical research sites, the ClinCard was selected for its proven ability to increase patient retention.

"By combining real-time patient payments in local currencies with automated patient messaging systems, the ClinCard system has been shown to increase patient retention by up to 11.7%, a particularly important consideration in a long-term study such as this," said Sam Whitaker, Greenphire's CEO and co-founder.  "I am pleased that the ClinCard solution can help to ensure the success of this study and that Greenphire's vision for automated payment processes is increasingly accepted within the industry as a way to reduce administration, costs, and risk in complex clinical trials."

About Greenphire

Greenphire is the industry's leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced web‐based payment technologies to help our clients improve operational efficiency, reduce costs, mitigate regulatory risks, increase subject retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.

Media Contact: Shana Jalbert Greenphire, (215) 948-9260, shana.jalbert@greenphire.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Greenphire
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuse Science Set to Redefine OTC and Pharmaceutical Delivery with Roll-On Application Technology
2. Micell Technologies Announces Issuance of Core Technology Patent
3. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
4. Study Published in Otology & Neurotology Shows Benefits of Cochlear Implant Sound Processor with Dual-Microphone Technology
5. LABSCO Implements Leading-Edge Technology to Support Growth and Seize Opportunities in the Clinical Laboratory Market
6. ECRI Institute Releases Top 10 Health Technology Hazards Report for 2013
7. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
8. Missouris PSE Blocking Technology Leading To Progress In Battle Against Meth
9. Kentuckys PSE Blocking Technology Leading To Progress In Battle Against Meth
10. Parker Signs Licensing Agreement with Vanderbilt for Exoskeleton Technology and Targets Commercial Launch in 2014
11. West Health Institute licenses Kinect-based physical therapy technology to Reflexion Health; West Health Investment Fund makes $4.25 million investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... of the Best Places to Work in the Research Triangle for 2017. , ... nominated, a company had to meet a threshold in employee participation--a percentage that ...
(Date:9/20/2017)... ... 2017 , ... Demand generation pioneer True Influence has announced ... The Marketing Tech Conference October 2–4, at the Hynes Convention Center in Boston, ... representing such thought-leading companies as JP Morgan Chase, GE Digital, and Dun & ...
(Date:9/20/2017)... ... ... In just a short time since going on sale on Wal-Mart Stores-owned ... trying the product for the first time, and others who had already been using ... Moore, MD, for everyone from athletes at risk from multiple concussions to elderly consumers ...
(Date:9/20/2017)... ... September 20, 2017 , ... Health & Safety Institute (HSI) ... HAZWOPER 8-, 24- and 40-Hour courses from now until November 30, 2017 to assist ... offering these discounted prices to all businesses and government agencies – whether or not ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm ... Friday, September 8, and Monday, September 11, off work and rolled up their sleeves ... before heading to local homes to start the process of rebuilding. , CORDA founder ...
Breaking Medicine News(10 mins):